GEHC

GEHC

USD

GE HealthCare Technologies Inc. Common Stock

$70.530+0.730 (1.046%)

Reaalajas hind

Healthcare
Health Information Services
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$69.800

Kõrge

$71.210

Madal

$69.380

Maht

1.00M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

32.3B

Tööstusharu

Health Information Services

Riik

United States

Kauplemisstatistika

Keskmine maht

4.69M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $57.65Praegune $70.530Kõrge $94.8

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 2. mai 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

GEHC: GE HealthCare Technologies Inc. Common Stock - Navigating Tariffs and Technical Signals

Stock Symbol: GEHC Generate Date: 2025-05-02 07:38:10

Alright, let's break down what's been happening with GE HealthCare lately. It's a bit of a mixed bag, so pay attention to the different pieces of the puzzle.

Recent News Buzz: What's the Vibe?

The feeling around GEHC right now is definitely complicated. On one hand, the company just reported its first quarter results, and guess what? They actually beat expectations. That's usually good news, right? They also saw strong growth in orders.

But here's the catch, and it's a big one: tariffs. New tariffs are expected to hit the company, particularly impacting their business in China. This concern is so significant that even though Q1 was strong, GE HealthCare had to slash its full-year outlook. That's a pretty serious move and it grabbed everyone's attention.

Because of this tariff cloud hanging overhead, several Wall Street analysts, even those who still like the stock and rate it a "Buy" or "Overweight," have felt compelled to lower their price targets. So, the core business might be doing okay now, but the future forecast is looking less sunny due to external factors.

Beyond the earnings and tariffs, there's also news about the company presenting at investor conferences and showcasing new technology, which are generally positive signs of ongoing business activity and innovation. But the tariff story is really dominating the headlines.

Price Check: What's the Stock Been Doing?

Looking at the stock chart over the last month or two tells a clear story. For a while there, through February and most of March, the price was trading relatively steadily, mostly bouncing around in the $80s.

Then, around the beginning of April, something changed dramatically. The stock took a sharp nosedive. We're talking a significant drop that pushed the price down into the $60s. It's been trading in that lower range since then.

The previous day's close was $67.67. Comparing this to the recent trend, it's clear the stock is trading at a much lower level than it was just a couple of months ago, reflecting that recent sharp decline.

Now, what about the very near future? The AI prediction model suggests a small upward move today, maybe around 1.8%. But then it predicts slight dips for the next two days (-0.54% and -0.67%). So, the AI sees some potential for a small bounce right now, but maybe not sustained upward momentum immediately after.

Putting It Together: Outlook & Ideas

So, we have a situation where the company had a good recent quarter, but the future outlook is dimmed by tariff worries, causing analysts to lower their targets even while maintaining positive ratings. The stock price has already taken a big hit, dropping significantly in the last month. The AI sees a small potential bump today but slight declines right after.

This is a classic case of conflicting signals. Good recent performance versus a challenging future forecast. A sharp price drop versus analysts still seeing long-term value (albeit with lower targets).

However, the provided recommendation data leans towards a "Bullish Momentum" view. It points to some technical indicators looking positive, like a surge in trading volume and a bullish signal from the MACD indicator. It also highlights the overall positive sentiment from analysts, noting an average price target significantly higher than the current price (around $96.45, suggesting substantial potential upside). The AI prediction data within the recommendation also projects an upward trend towards $90.96, which seems to contradict the very short-term daily predictions but suggests a more positive view over a slightly longer horizon.

Given the sharp recent decline and these underlying bullish signals from the recommendation data, the current situation might be seen by some as a potential buying opportunity, assuming the market has overreacted to the tariff news or that the long-term picture remains strong.

If you were considering getting involved, the provided analysis suggests potential entry points around the $70.13 to $70.61 area. The stock closed just below that yesterday, so the current price area could be one place to watch.

For managing risk, the analysis suggests a potential stop-loss level at $63.25. This is a point below recent lows, where you might consider exiting to limit potential losses if the price continues to fall. On the flip side, a potential take-profit level is suggested at $75.47. This is a point where you might consider selling to lock in gains if the stock moves up. Remember, these are just potential levels based on the analysis provided, not guarantees.

Company Context

Just to keep the bigger picture in mind, GE HealthCare is a major player in the Healthcare sector, specifically in Health Information Services. They make and sell a wide range of medical equipment and solutions, from imaging machines like MRIs and X-rays to patient monitoring systems and diagnostic agents. With 53,000 employees, they're a substantial global business. So, news like tariffs impacting international trade, especially in a key market like China, is particularly relevant to their operations and future prospects.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

BusinessWire

ESTRO 2025 Congress: GE HealthCare to expand its radiation oncology portfolio and introduce new AI-enabled solutions

The company will showcase innovations designed to optimize the oncology care workflow and enable improved patient outcomes GE HealthCare (NASDAQ:GEHC) today announced an intended expansion of its radiation oncology

Vaata rohkem
ESTRO 2025 Congress: GE HealthCare to expand its radiation oncology portfolio and introduce new AI-enabled solutions
Analyst Upgrades

GE HealthCare's Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025

GE HealthCare beats Q1 estimates and sees strong order growth, but tariff concerns prompt analysts to cut price targets despite a positive outlook.

Vaata rohkem
GE HealthCare's Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025
Analyst Upgrades

Goldman Sachs Maintains Buy on GE HealthCare Techs, Lowers Price Target to $82

Goldman Sachs analyst David Roman maintains GE HealthCare Techs with a Buy and lowers the price target from $94 to $82.

Vaata rohkem
Goldman Sachs Maintains Buy on GE HealthCare Techs, Lowers Price Target to $82
Analyst Upgrades

Wells Fargo Maintains Overweight on GE HealthCare Techs, Lowers Price Target to $89

Wells Fargo analyst Larry Biegelsen maintains GE HealthCare Techs with a Overweight and lowers the price target from $103 to $89.

Vaata rohkem
Wells Fargo Maintains Overweight on GE HealthCare Techs, Lowers Price Target to $89
Analyst Upgrades

Evercore ISI Group Maintains Outperform on GE HealthCare Techs, Lowers Price Target to $85

Evercore ISI Group analyst Vijay Kumar maintains GE HealthCare Techs with a Outperform and lowers the price target from $96 to $85.

Vaata rohkem
Evercore ISI Group Maintains Outperform on GE HealthCare Techs, Lowers Price Target to $85
Analyst Upgrades

Citigroup Maintains Buy on GE HealthCare Techs, Lowers Price Target to $86

Citigroup analyst Joanne Wuensch maintains GE HealthCare Techs with a Buy and lowers the price target from $105 to $86.

CNBC

GE HealthCare beats on earnings, slashes full year outlook due to tariffs

GE HealthCare beats on earnings, slashes full year outlook due to tariffs

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 3. mai 2025, 07:43

LangevNeutraalneTõusev

56.9% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
VäärtusKonservatiivne
Kauplemisjuhend

Sisenemispunkt

$70.62

Võta kasum

$71.89

Peata kahjum

$63.43

Põhitegurid

DMI näitab langustrendi (ADX:22.4, +DI:4.9, -DI:6.9), mis viitab ettevaatlikkusele
Praegune hind on tugitasemele ($70.69) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 9.0x keskmisest (57,276), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0285 on signaalijoone 0.0566 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.